Leading Cancer Visualization

As minimally invasive and robotic-assisted surgery have become the standard of care for many cancer surgeries, Vergent is focused on helping surgeons realize the full potential of these procedures by significantly improving the visibility of tumors.

The company is developing tumor-targeted agents that enhance surgeons’ ability to visualize tumors intraoperatively, making cancer surgery more successful for them and their patients.

Vergent’s lead program, VGT-309, is a targeted fluorescent-imaging agent. The company is currently sponsoring a Phase 2 clinical study evaluating VGT-309 in lung cancer surgeries at the University of Pennsylvania.

Bringing together an innovative imaging agent, a commitment to rigorous science, and a world-class leadership team, Vergent Bioscience is positioned to become the global leader in intraoperative cancer surgery.